The Majority of Surveyed Clinicians Who Have Prescribed Nucynta for Inflammatory and Nociceptive Pain Perceive the Drug to Have Efficacy That is Comparable to Oxycodone
Advertisement
However, Nucynta and Embeda - Which Both Launched in 2009 - Are Still Excluded From Many Commercial and Medicare Drug Plans, According to a New Report from Decision Resources
